BXQ-350 has an entirely new and novel mechanism of action. Studies strongly suggest
that specific tumor targeting is the result of targeting phosphatidylserine patches
that are characteristic of tumor cells and neovasculature; and that apoptosis results
from activation of acid sphingomyelinase, subsequent generation of ceramide, and
elevated levels of caspase [Qi et al. (2009) Clin Cancer Res 15(18):5840–5851; Grammatikos
et al. (2007) Antioxidants & Redox Sign. 9:1449-1456].